Back to top
more

Integer Holdings (ITGR)

(Delayed Data from NYSE)

$106.83 USD

106.83
243,843

+0.31 (0.29%)

Updated Aug 4, 2025 04:00 PM ET

After-Market: $106.89 +0.06 (0.06%) 4:42 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth D Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 36% (158 out of 246)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Masimo's (MASI) LiDCO to Boost Hemodynamic Monitoring Post CE Mark

by Zacks Equity Research

Masimo's (MASI) LiDCO is likely to offer clinicians a BIC solution designed to provide a more complete picture of oxygen delivery.

Zacks Equity Research

3 Reasons to Add Surmodics (SRDX) Stock to Your Portfolio

by Zacks Equity Research

Surmodics' (SRDX) solid prospects in the thrombectomy business raise optimism about the stock.

Zacks Equity Research

3 Reasons to Retain Inogen (INGN) Stock in Your Portfolio

by Zacks Equity Research

Inogen's (INGN) potential in the POC space and a strong product portfolio raise optimism about the stock.

Zacks Equity Research

Veradigm (MDRX)-FDB Vela to Enhance Pharmacy Connectivity

by Zacks Equity Research

Veradigm's (MDRX) latest progress with FDB Vela is likely to offer prescribers and patients greater choice and cost transparency.

Zacks Equity Research

Three Reasons to Add PacBio (PACB) Stock to Your Portfolio

by Zacks Equity Research

PacBio's (PACB) product development activities raise optimism about the stock.

Zacks Equity Research

OPKO Health (OPK) Gets BARDA Contract to Combat Antibody Threats

by Zacks Equity Research

OPKO Health's (OPK) latest awarded funding is likely to enable the development of novel multispecific antibodies against viral infectious disease threats.

Zacks Equity Research

3 Reasons to Add Merit Medical (MMSI) Stock to Your Portfolio

by Zacks Equity Research

Merit Medical's (MMSI) strong product portfolio raises optimism about the stock.

Zacks Equity Research

Veradigm (MDRX) Advances Tie-Up to Enhance Care Delivery

by Zacks Equity Research

Veradigm's (MDRX) new phase of strategic investment is likely to drive innovation and close the evidence gap in behavioral health.

Zacks Equity Research

AngioDynamics (ANGO) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

AngioDynamics (ANGO) delivered earnings and revenue surprises of 14.29% and 1.32%, respectively, for the quarter ended August 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Accuray's (ARAY) New Offering to Boost Radiation Treatment Plans

by Zacks Equity Research

Accuray's (ARAY) latest offering is likely to improve radiation treatment.

Zacks Equity Research

Here's Why You Should Retain Zimmer Biomet (ZBH) for Now

by Zacks Equity Research

Investors are optimistic about Zimmer Biomet (ZBH) on business recovery and expansion in emerging markets.

Zacks Equity Research

Veradigm's (MDRX) New Tie-Up to Boost Patients' Health Outcomes

by Zacks Equity Research

Veradigm's (MDRX) latest partnership is likely to promote value-based care initiatives for healthcare providers and the patients they serve.

Zacks Equity Research

Here's Why You Should Retain Ecolab (ECL) Stock for Now

by Zacks Equity Research

Ecolab's (ECL) strength in its business raises optimism about the stock.

Zacks Equity Research

Here's Why You Should Retain Medtronic (MDT) Stock for Now

by Zacks Equity Research

Investors are optimistic about Medtronic (MDT) on strong global expansion.

Zacks Equity Research

3 Reasons to Hold Catalent (CTLT) Stock in Your Portfolio

by Zacks Equity Research

Catalent's (CTLT) product and service launches and a slew of strategic deals raise optimism about the stock.

Zacks Equity Research

Here's Why You Should Invest in Penumbra (PEN) Stock for Now

by Zacks Equity Research

Investors are optimistic about Penumbra (PEN), driven by growth in vascular and neuro businesses.

Zacks Equity Research

Here's Why Investors Should Retain Omnicell (OMCL) Stock Now

by Zacks Equity Research

Investors are optimistic about Omnicell (OMCL), led by its digital transformation strategy.

Zacks Equity Research

Here's Why You Should Retain Inspire Medical (INSP) Stock Now

by Zacks Equity Research

Inspire Medical's (INSP) focus on R&D raises optimism about the stock.

Zacks Equity Research

NextGen (NXGN) Extends Agreement to Boost Athletico's Footprint

by Zacks Equity Research

NextGen's (NXGN) latest extended agreement is likely to reflect its solutions' potential to aid healthcare organizations at all stages of growth.

Zacks Equity Research

Here's Why Investors Should Invest in Abbott (ABT) Stock Now

by Zacks Equity Research

Investors are optimistic about Abbott (ABT) on strong growth in the Diagnostics business and upbeat guidance.

Zacks Equity Research

QIAGEN (QGEN) Extends QIAwave Product Line With New Kit

by Zacks Equity Research

QIAGEN's (QGEN) new QIAwave kits broaden its selection of environmentally friendly products and reaffirm its commitment to helping researchers advance science.

Zacks Equity Research

QuidelOrtho's (QDEL) Rapid Antigen Test Gets CLIA Waiver

by Zacks Equity Research

QuidelOrtho's (QDEL) receipt of the FDA's CLIA waiver is expected to widen access to the rapid antigen test in any point-of-care setting equipped with Sofia 2 instruments.

Zacks Equity Research

3 Reasons to Hold HealthEquity (HQY) Stock in Your Portfolio

by Zacks Equity Research

HealthEquity's (HQY) strength in HSA raises optimism about the stock.

Zacks Equity Research

Abbott (ABT) Closes Acquisition Deal of Bigfoot Biomedical

by Zacks Equity Research

Abbott's (ABT) footprint in the diabetes care market is increased by the Bigfoot Biomedical acquisition.

Zacks Equity Research

3 Reasons to Hold Veeva Systems (VEEV) Stock in Your Portfolio

by Zacks Equity Research

Veeva Systems' (VEEV) strong product portfolio raises optimism about the stock.